---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016877"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:26:08.200064+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM

## Summary
- Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.
- Cash and equivalents of $190.7M; runway projected through 2027.
- Files $300M universal shelf registration and $75M at-the-market (ATM) equity facility with Leerink Partners.
- PIPE-791 Phase 1b PET topline data expected Q2 2025; Phase 2 initiation in IPF and PrMS planned H2 2025.
- PIPE-307 Phase 2 VISTA RRMS topline data anticipated H2 2025; J&J Phase 2 MDD trial recruiting.

## SEC filing metadata
- accession: 0001437749-25-016877
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/0001437749-25-016877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925016877/cont20250321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016877
- JSON: https://secwatch.observer/filing/0001437749-25-016877.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.